AC 410

Drug Profile

AC 410

Alternative Names: AC-410

Latest Information Update: 18 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ambit Biosciences Corporation
  • Developer Daiichi Sankyo Company
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Autoimmune disorders; Inflammation

Most Recent Events

  • 10 Nov 2014 Ambit Biosciences Corporation has been acquired by Daiichi Sankyo Company
  • 10 Apr 2014 Phase-I clinical trials in Inflammation in USA (PO) prior to April 2014
  • 08 Apr 2014 Phase-I clinical trials in Autoimmune disorders in USA (PO) prior to April 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top